News

For the quarter ended December 2023, Alkermes (ALKS) reported revenue of $377.48 million, up 23.9% over the same period last year. EPS came in at $0.48, compared to $0.14 in the year-ago quarter.

The reported revenue represents a surprise of +4.50% over the Zacks Consensus Estimate of $361.24 million. With the consensus EPS estimate being $0.46, the EPS surprise was +4.35%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Alkermes performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenues- Manufacturing and Royalty revenues: $135.50 million compared to the $123.97 million average estimate based on six analysts. The reported number represents a change of +53% year over year.
• Revenues- Product sales, net: $241.97 million versus the six-analyst average estimate of $241.45 million. The reported number represents a year-over-year change of +12%.
• Revenues- Key Commercial Product Revenues- LYBALVI: $56.22 million versus the three-analyst average estimate of $54.62 million.
• Revenues- Key Commercial Product Revenues- VUMERITY: $33.60 million versus $31.89 million estimated by three analysts on average.
• Revenues- Key Commercial Product Revenues- ARISTADA: $83.37 million versus the three-analyst average estimate of $84.07 million. The reported number represents a year-over-year change of +5.2%.
• Revenues- Key Commercial Product Revenues- VIVITROL: $102.39 million versus $101.95 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +0.4% change.
• Revenues- Research and development revenue: $0 million compared to the $0.59 million average estimate based on two analysts. The reported number represents a change of -72.7% year over year.

View all Key Company Metrics for Alkermes here>>>

Shares of Alkermes have returned +1.1% over the past month versus the Zacks S&P 500 composite's +4.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Zacks Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

It’s credited with a “watershed medical breakthrough” and is developing a bustling pipeline of other projects that could make a world of difference for patients suffering from diseases involving the liver, lungs, and blood. This is a timely investment that you can catch while it emerges from its bear market lows.

It could rival or surpass other recent Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.

Free: See Our Top Stock And 4 Runners Up

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.